SHR2554 Tablets

DRUG4 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., The First Affiliated Hospital with Nanjing Medical University

Conditions

Advanced Gastric CancerGastroesophageal Junction AdenocarcinomaMalignant TumorMetastatic Gastric CancerPTCLProstate Cancer

Phase 1

Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects

CompletedNCT05661591

Jiangsu HengRui Medicine Co., Ltd.Malignant Tumor

Start: 2023-02-28End: 2023-03-31Updated: 2023-04-04

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

RecruitingNCT06568094

Jiangsu HengRui Medicine Co., Ltd.Prostate Cancer

Start: 2024-09-25End: 2027-06-30Target: 100Updated: 2025-12-31

Phase 2

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

RecruitingNCT07102901

Jiangsu HengRui Medicine Co., Ltd.Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Cancer

Start: 2025-09-05End: 2027-12-31Target: 351Updated: 2025-09-10

SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma

Not yet recruitingNCT07347288

The First Affiliated Hospital with Nanjing Medical UniversityPTCL

Start: 2026-02-01End: 2029-06-01Target: 30Updated: 2026-01-16